The gut-joint connection: what the research now shows

For decades, osteoarthritis has been explained as wear and tear — the inevitable consequence of an ageing body working hard. That explanation is being rewritten.

Research published in the journal Science in 2025 has established, for the first time, a direct and functional connection between the gut microbiome and joint health. It is not a loose association. It is a specific, named biological pathway — and it changes what we should be thinking about when we think about protecting our joints.

What the research found

The study analysed metabolomic data from 1,868 individuals across two independent cohorts. The finding was consistent: people with osteoarthritis showed significantly lower levels of a bile acid called GUDCA compared to people without the condition. The lower the GUDCA, the more severe the joint disease.

The mechanism behind this matters. A specific gut bacterium, Clostridium bolteae, produces bile acids including UDCA and GUDCA. These acids act on a receptor in the intestinal lining called FXR, which triggers specialised gut cells to produce GLP-1 — the same signalling molecule now widely known for its metabolic effects. This gut-derived GLP-1 travels through the bloodstream to the joints, where GLP-1 receptors are present in joint tissue. There it acts as a biological brake on cartilage degradation.

In people with osteoarthritis, C. bolteae is consistently depleted. So is GUDCA. So is the GLP-1 signal that reaches the joint. The brake is gone.

This is not a future possibility

The researchers also examined real-world data from nearly 6,000 patients taking UDCA — a drug already approved for other conditions. Those patients had a meaningfully lower risk of requiring joint replacement surgery. The pathway from gut health to joint protection is not theoretical. It has been validated in human populations.

What it means for the window before diagnosis

The most significant implication of this research is about timing. The depletion of C. bolteae and GUDCA is not a consequence of severe osteoarthritis — it is associated with its progression from early stages. The gut-joint pathway fails quietly, long before joints become painful enough to warrant a GP visit.

For the millions of people who notice stiffness after sitting, slower recovery after exercise, or joints that take longer to warm up — but who have no diagnosis and no clinical intervention available — this research identifies a biological mechanism that may already be in decline.

The treatment gap

Current medical practice offers two things for osteoarthritis: pain management and, eventually, joint replacement. There is nothing in between that addresses the underlying biology. No intervention targets the gut-joint axis in the preventive window. Drug development timelines mean pharmaceutical options targeting this pathway are years away from reaching patients.

The research itself points toward what that intervention might look like — restoring the gut microbiome conditions that sustain C. bolteae, supporting bile acid metabolism, and maintaining the GLP-1 signal that protects joint tissue.

Further reading

Yang et al. (2025). Gut microbiota–bile acid–GLP-1 axis in osteoarthritis. Science. doi:10.1126/science.adt0548

LYVA Flex is formulated around the biology described in this article. Read the science or join the waitlist for founding member pricing.

— William Tyler-Street, Founder